DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR MS Speaks
       *****************************************************
   DIR (Abst.) Effect of Ocrevus on vaccine responses in patients w/MS
       0 replies
   DIR (Abst.) Adverse event profile differences between Rituxan and ...
       1 replies
   DIR (Abst.) Varicella zoster immunity loss in MS patient treated w...
       0 replies
   DIR (Abst.) Switching to Ocrevus in RRMS patients at risk of PML p...
       0 replies
   DIR 2-hour Ocrevus infusion time OK'd in Europe
       0 replies
   DIR 1st PML case with ocrelizumab alone reported
       2 replies
   DIR Ocrelizumab approved for "early PPMS" in Scotland
       0 replies
   DIR (Abst.) Two meningitis cases associated with ocrelizumab therapy
       0 replies
   DIR Ocrelizumab and liver injury research information (PubMed)
       0 replies
   DIR (ECTRIMS) Rituxan vs. Ocrevus
       0 replies
       *****************************************************
       Page 5 of 10
   DIR Previous Page
   DIR Next Page